• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » L-Methylfolate May Offer Modest Boost to Antidepressants
Research Update

L-Methylfolate May Offer Modest Boost to Antidepressants

April 14, 2023
Glen Spielmans, PhD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Glen Spielmans, PhD. Dr. Spielmans has no financial relationships with companies related to this material.

REVIEW OF: Maruf AA et al, Pharmacopsychiatry 2022;55(3):139–147

STUDY TYPE: Meta-analysis

L-methylfolate is a metabolite of dietary folate and is approved by the FDA as a medical food for the adjunctive treatment of depression. Approval of medical foods does not require the same level of rigor as actual approval of a medication, and therefore researchers conducted a meta-analysis scrutinizing the strength of the available empirical evidence for L-methylfolate in depression.

A systematic literature search turned up only four randomized placebo-controlled trials of methylfolate as an adjunct to antidepressant treatment. Most of the trials added methylfolate after failure of an antidepressant, usually an SSRI or SNRI. Two enrolled patients with treatment-resistant depression (n=265), while the other two included patients without treatment resistance (n=284). Three trials used 15 mg/day dosing, while one used 7.5 mg. Trial duration ranged from one month to six months. Results showed a modest treatment effect on Hamilton Depression Rating Scale scores (effect size 0.38, p<0.001) and a similar effect on response rate (RR=1.26, p=0.005). The 7.5 mg dose showed no efficacy—only the 15 mg dose was effective.

The analysis had several limitations. One of the trials lacked clarity on the psychiatric medications that subjects were taking in addition to L-methylfolate, and two of the trials lacked specific data on adverse events. Two were industry sponsored, and the small number of published studies leaves open the possibility that any (unknown) unpublished studies with negative findings could greatly reduce the apparent effect of L-methylfolate.

On the other hand, the authors did not include a large randomized controlled monotherapy trial (n=330) of Enlyte, presumably because this FDA-cleared product contains other folate and B vitamins in addition to 7.5 mg of L-methylfolate. Enlyte had a large effect size (0.88) as monotherapy in this clinical trial. The patients had moderate depression, some treatment resistant and some not, but all were selected for genetic polymorphisms on the MTHFR gene (C677T or A1298C), making it difficult to compare the results with those of the traditional L-methylfolate studies. In theory, these patients may be more likely to respond to L-methylfolate, but that theory has not been clinically tested, and we do not recommend routine genetic testing before starting L-methylfolate (Mech AW and Farah A, J Clin Psychiatry 2016;77(5):668–671).

L-methylfolate is available by prescription or over the counter (eg, Opti-Folate is available as 15 mg tabs for $8/month), while Enlyte is prescription-only ($52/month if not covered by insurance, at www.enlyterx.com).

CARLAT TAKE

Coprescribing L-methylfolate may offer a modest boost to antidepressants and is a reasonable choice for patients who want a natural or well-tolerated option. Both standard L-methylfolate and Enlyte are reasonable options.


General Psychiatry Research Update
KEYWORDS antidepressants bipolar disorder l-methylfolate meta-analysis mood disorders
    Ccpr octnovdec2020 qa1 headshot spielmans 150x150
    Glen Spielmans, PhD

    Is Dose Reduction the Ideal Strategy after First Episode of Psychosis?

    More from this author
    www.thecarlatreport.com
    Issue Date: April 14, 2023
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Psychocardiology, TCPR, April/May 2023
    When Shorter Is Better
    Cardiovascular Psychiatry: Part 1
    Cardiovascular Psychiatry: Part 2
    Music for Sleep
    Do Antidepressants Have Any Role in Acute Bipolar Depression?
    L-Methylfolate May Offer Modest Boost to Antidepressants
    Can Abstaining From Social Media Help People Feel Better?
    Marginal Results for Levetiracetam in Mania
    A New Intervention for Shift-Work Disorder
    An End to YAVIS Syndrome?
    The Center Cannot Hold: My Journey Through Madness
    CME Post-Test, Psychocardiology, TCPR, April/May 2023
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.